CAS: 213261-59-7; (5,5'-(Furan-2,5-Diyl)Bis(Thiophene-5,2-Diyl))Dimethanol
该化合物是有机化合物,其独特结构具有其独特性,其特点是与两个硫苯乙醇单位相连的松软动物,该化合物具有典型的呋喃衍生物和硫苯衍生物的特性,包括由于存在硫苯环而具有的潜在电子施食特性;呋喃环有助于其再活性,特别是在电子替代反应方面;硫乙醇单位中的氢氧基基可参与氢联结,影响化合物的溶性以及与其他分子的相互作用;该化合物可能具有有趣的光学和电子特性,成为有机电子学应用的候选物,例如有机发光二极管或有机光伏.此外,其结构特征可能会传播生物活动,保证对药用化学进行进一步调查.
物理性质
- 熔点160 °C
- 沸点464.9±40.0 °C at 760 mmHg
- 闪点235.0±27.3 °C
- 密度1.4±0.1 g/cm3
- pKa:13.43±0.10(预测)
- PSA:110.08
- LogP:2.48
- 折射率1.661
- 蒸汽压0.0±1.2 mmHg at 25°C
- 溶解性Soluble In DMSO (Up To 20 mg/mL)
- 敏感性光敏感
- 外观形态黄色结晶性固体
- 储存条件置于阴暗处,密封干燥,冷冻保存, 低于 -20°C
- 产品应用该化合物是诱发DNA-蛋白质和DNA-DNA-DNA交叉链接而不会导致单层DNA破碎的P53活性;它抑制MDM2-P53互动,导致P53稳定并激活;它显示出有选择性的细胞毒性,包括ACHN和UO-31等各种癌症细胞线(IC50=13微M和37微M),并诱发10NM的G2-M细胞循环阻截,DNA破片和100 NM的吸附病,提高P53蛋白水平,促进P53 SER46磷化,并通过对磷酸化的ASK-1,MKK-4和C-JUN进行升级管制,激活JNK信号路径.它明显抑制了P53依赖的HCT116肿瘤细胞生长(97%),但对HCT 116 TP53-NUM细胞的影响很小.在VIVO, RITA在小鼠体内非常容忍,在10毫克/千克的抑制下,一个月后没有观察到重大重量损失.
MSDS等安全信息
上下游产品
5-(5-bromofuran-2-yl)thiophene-2-carbaldehyde (5-(5-bromofuran-2-yl)thiophen-2-yl)methanol 5-bromo-2-thiophencarboxaldehyde合成工艺路线路线简述
📜5-溴噻吩-2-甲醛置于sodium Tetrahydroborate,N-溴代丁二酰亚胺(Nbs),Palladium Diacetate,Potassium Carbonate,2-二环己基磷-2,4,6-三异丙基联苯,过氧化苯甲酰体系中,用 四氢呋喃,甲醇,二氯甲烷,水,甲苯,乙腈 用作溶剂,化学反应 29.0H,反应生成5,5'-(2,5-呋喃二基)二-2-噻吩甲醇
参考文献:Rita及其类似物的有效合成:通过调节p53 / Mir-34A途径获得具有增强的抗增殖活性的类似物†
标题:Rita及其类似物的有效合成:通过调节p53 / Mir-34A途径获得具有增强的抗增殖活性的类似物†
摘要:开发了一种在室温下通过实际的钯催化的cc键形成的suzuki反应合成rita的新方法,该方法用于衍生一系列取代的三环α-杂芳基(呋喃/噻吩)在温和条件下的rita类似物.这些新颖的类似物对具有野生型p53(即hct116,A549,Mcf-7和k562)的癌细胞系表现出显着的抗增殖活性,但在hct116 / P53-/-细胞中的活性却低得多.特别是,化合物1F表明相比rita有前途的抗增殖活性,与ic 50 = 28纳米的mcf-7与54纳米的rita,和癌细胞的选择性.化合物1F以100 Nm的浓度显着激活了hct116细胞中的p53,触发了细胞凋亡.重要的是,我们发现rita和化合物1F均可诱导g 0 / G 1通过上调mir-34A抑制细胞周期,而mir-34A则下调细胞周期相关蛋白cdk4和e2F1的表达.总而言之,这项研究报告了一种有效的rita及其类似物的合成方法,并阐明了这些化合物的新型抗增殖机制.
Doi:10.1039/c2Ob26627J
海关参考信息
- 2905110000-甲醇
- 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2023037284-A9
优先权日:2018-11-30
标题:Combination therapy of peptidomimetic macrocycles
发明人：GUERLAVAIS VINCENT; ANNIS DAVID ALLEN
权利人:AILERON THERAPEUTICS INC
摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.
专利号:US-2018371021-A1
优先权日:2017-05-11
标 题 :Peptidomimetic macrocycles and uses thereof
发明人：AIVADO MANUEL; GUERLAVAIS VINCENT; OLSON KAREN
权利人:AILERON THERAPEUTICS INC
摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.
专利号:SA-109300715-B1
优先权日:2008-12-01
标 题 :Synthesis of (R)-3-((E)-2-(pyrrolidine-3-yl)-phenyl)-5-(tetrahydropyrane-4-yloxy)pyridine and forms new salts thereof
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Xu J, Eriksson SE, Cebula M, Sandalova T, Hedström E, Pader I, Cheng Q, Myers CR, Antholine WE, Nagy P, Hellman U, Selivanova G, Lindqvist Y, Arnér ES. The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death. Cell Death Dis. 2015 Jan 22;6:e1616. doi: 10.1038/cddis.2014.574. doi: 10.1371/journal.pone.0104821. eCollection 2014.
3: Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 2014 Jul 10;5:e1318. doi: 10.1038/cddis.2014.284.
4: Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17. doi: 10.1007/s10495-012-0790-6. doi: 10.1039/c2ob26627j. Epub 2012 Nov 15. doi: 10.1038/cdd.2012.112. Epub 2012 Aug 31.
合成参考文献
参考文献:10.1021/acsmedchemlett.6b00488
摘要:Pietkiewicz AL, Zhang Y, Rahimi MN, Stramandinoli M, Teusner M, McAlpine SR. RITA Mimics: Synthesis and Mechanistic Evaluation of Asymmetric Linked Trithiazoles. ACS Med. Chem. Lett. 2017 Mar 09;8(4):401–6. doi: 10.1021/acsmedchemlett.6b00488.
参考文献:10.1124/mol.119.115964
摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
参考文献:10.1007/978-981-99-3810-0_52
摘要:Gill H, Lee E, Mo P. In the Pipeline: Emerging Therapy for CML. 2023. In: Pathogenesis and Treatment of Leukemia.
参考文献:10.1186/s43042-024-00616-0
摘要:Wang F, Chen L, Zhang L, Du S, Feng Y. Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis. Egypt J Med Hum Genet. 2024 Dec 16;25(1). doi: 10.1186/s43042-024-00616-0.
📝 需求与反馈
尽可能描述清楚需求与问题信息
